Recruiting PHASE1 INTERVENTIONAL 1-arm NCT05650580

TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

A Phase I Clinical Study to Characterize Safety, Tolerability, and Pharmacokinetics of TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

Sponsor: Tarapeutics Science Inc.

Conditions Advanced Solid Tumor Non-Hodgkin's Lymphoma Refractory Non-Hodgkin's Lymphoma, Relapsed

Interventions TR115

Updated 5 times since 2023 Last updated: May 13, 2024 Started: Apr 23, 2023 Primary completion: Jul 30, 2025 Completion: Dec 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05650580, this PHASE1 trial focuses on Advanced Solid Tumor and Non-Hodgkin's Lymphoma Refractory and remains actively recruiting participants. Sponsored by Tarapeutics Science Inc., it has been updated 5 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1
May 2023 — Jun 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jan 2023 — May 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tarapeutics Science Inc.

Data source: Tarapeutics Science Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China